The Role of GNMT and MMP12 Expression in Determining TACE Efficacy: Validation at Transcription and Protein Levels

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450–1462. doi:10.1056/NEJMra1713263
   PubMed Web of Science ®Google Scholar
• Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. doi:10.1038/nrdp.2016.18
   PubMed Web of Science ®Google Scholar
• Lee TK, Guan XY, Ma S. Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications. Nat Rev Gastroenterol Hepatol. 2022;19(1):26–44. doi:10.1038/s41575-021-00508-3
   PubMedGoogle Scholar
• Chang Y, Jeong SW, Young Jang J, Jae Kim Y. Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma. Int J Mol Sci. 2020;21(21). doi:10.3390/ijms21218165
   Web of Science ®Google Scholar
• Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11(9):525–535. doi:10.1038/nrclinonc.2014.122
   PubMed Web of Science ®Google Scholar
• Habib A, Desai K, Hickey R, Thornburg B, Lewandowski R, Salem R. Transarterial approaches to primary and secondary hepatic malignancies. Nat Rev Clin Oncol. 2015;12(8):481–489. doi:10.1038/nrclinonc.2015.78
   PubMed Web of Science ®Google Scholar
• Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64(1):106–116. doi:10.1002/hep.28453
   PubMed Web of Science ®Google Scholar
• Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S179–188. doi:10.1053/j.gastro.2004.09.032
   PubMed Web of Science ®Google Scholar
• Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements. J Hepatol. 2020;72(2):288–306. doi:10.1016/j.jhep.2019.09.026
   PubMed Web of Science ®Google Scholar
• Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis. 2011;29(3):339–364. doi:10.1159/000327577
   PubMed Web of Science ®Google Scholar
• Yang C, Luo YG, Yang HC, Yao ZH, Li X. Effects of Early TACE Refractoriness on Survival in Patients with Hepatocellular Carcinoma: a Real-World Study. J Hepatocell Carcinoma. 2022;9:621–631. doi:10.2147/JHC.S373112
   PubMedGoogle Scholar
• Niu XK, He XF. Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma. World J Gastroenterol. 2021;27(2):189–207. doi:10.3748/wjg.v27.i2.189
   PubMed Web of Science ®Google Scholar
• Maesaka K, Sakamori R, Yamada R, et al. Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma. Hepatol Res. 2020;50(3):365–373. doi:10.1111/hepr.13446
   PubMed Web of Science ®Google Scholar
• Fako V, Martin SP, Pomyen Y, et al. Gene signature predictive of hepatocellular carcinoma patient response to transarterial chemoembolization. Int J Biol Sci. 2019;15(12):2654–2663. doi:10.7150/ijbs.39534
   PubMed Web of Science ®Google Scholar
• He Q, Yang J, Jin Y. Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma. Front Immunol. 2022;13:869993. doi:10.3389/fimmu.2022.869993
   PubMed Web of Science ®Google Scholar
• Shi M, Lu LG, Fang WQ, et al. Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. J Natl Cancer Inst. 2013;105(1):59–68. doi:10.1093/jnci/djs464
   PubMedGoogle Scholar
• Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol. 2013;10(1):34–42. doi:10.1038/nrgastro.2012.199
   PubMed Web of Science ®Google Scholar
• Roessler S, Jia HL, Budhu A, et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010;70(24):10202–10212. doi:10.1158/0008-5472.CAN-10-2607
   PubMed Web of Science ®Google Scholar
• Wei X, Zhao L, Ren R, et al. MiR‐125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma. Hepatology. 2021;73(4).
   Web of Science ®Google Scholar
• Sun HC, Tang ZY. Preventive treatments for recurrence after curative resection of hepatocellular carcinoma--A literature review of randomized control trials. World J Gastroenterol. 2003;9(4):635–640. doi:10.3748/wjg.v9.i4.635
   PubMed Web of Science ®Google Scholar
• Newman AM, Steen CB, Liu CL, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773–782. doi:10.1038/s41587-019-0114-2
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi:10.1038/s41591-018-0136-1
   PubMed Web of Science ®Google Scholar
• Martinez-Chantar ML, Vazquez-Chantada M, Ariz U, et al. Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology. 2008;47(4):1191–1199. doi:10.1002/hep.22159
   PubMed Web of Science ®Google Scholar
• Frau M, Feo F, Pascale RM. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis. J Hepatol. 2013;59(4):830–841. doi:10.1016/j.jhep.2013.04.031
   PubMed Web of Science ®Google Scholar
• Li CH, Yen CH, Chen YF, et al. Characterization of the GNMT-HectH9-PREX2 tripartite relationship in the pathogenesis of hepatocellular carcinoma. Int J Cancer. 2017;140(10):2284–2297. doi:10.1002/ijc.30652
   PubMed Web of Science ®Google Scholar
• Martínez–López N, García–Rodríguez JL, Varela–Rey M, et al. Hepatoma Cells From Mice Deficient in Glycine N-Methyltransferase Have Increased RAS Signaling and Activation of Liver Kinase B1. Gastroenterology. 2012;143(3):787–798.e713. doi:10.1053/j.gastro.2012.05.050
   PubMed Web of Science ®Google Scholar
• Hughey CC, James FD, Wang Z, Goelzer M, Wasserman DH. Dysregulated transmethylation leading to hepatocellular carcinoma compromises redox homeostasis and glucose formation. Mol Metab. 2019;23:1–13. doi:10.1016/j.molmet.2019.02.006
   PubMed Web of Science ®Google Scholar
• Ma R, Zhang W, Tang K, et al. Switch of glycolysis to gluconeogenesis by dexamethasone for treatment of hepatocarcinoma. Nat Commun. 2013;4:2508. doi:10.1038/ncomms3508
   PubMed Web of Science ®Google Scholar
• Hughey CC, Trefts E, Bracy DP, James FD, Donahue EP, Wasserman DH. Glycine N-methyltransferase deletion in mice diverts carbon flux from gluconeogenesis to pathways that utilize excess methionine cycle intermediates. J Biol Chem. 2018;293(30):11944–11954. doi:10.1074/jbc.RA118.002568
   PubMed Web of Science ®Google Scholar
• Chen M, Zhang J, Li N, et al. Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer. PLoS One. 2011;6.
   Google Scholar
• Hirata H, Sugimachi K, Komatsu H, et al. Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma. Cancer Res. 2016;76(11):3265–3276. doi:10.1158/0008-5472.CAN-15-2601
   PubMed Web of Science ®Google Scholar
• Kowalik MA, Columbano A, Perra A. Emerging Role of the Pentose Phosphate Pathway in Hepatocellular Carcinoma. Front Oncol. 2017;7:87. doi:10.3389/fonc.2017.00087
   PubMed Web of Science ®Google Scholar
• Sato E, Mori T, Mishima E, et al. Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease. Sci Rep. 2016;6:36618. doi:10.1038/srep36618
   PubMed Web of Science ®Google Scholar
• Stincone A, Prigione A, Cramer T, et al. The return of metabolism: biochemistry and physiology of the pentose phosphate pathway. Biol Rev Camb Philos Soc. 2015;90(3):927–963. doi:10.1111/brv.12140
   PubMed Web of Science ®Google Scholar
• Cong T, Luo Y, Fu Y, Liu Y, Li Y, Li X. New perspectives on ferroptosis and its role in hepatocellular carcinoma. Chin Med J (Engl). 2022;135(18):2157–2166. doi:10.1097/CM9.0000000000002327
   PubMed Web of Science ®Google Scholar
• Martinez-Chantar ML, Lu SC, Mato JM, et al. The role of stem cells/progenitor cells in liver carcinogenesis in glycine N-methyltransferase deficient mice. Exp Mol Pathol. 2010;88(2):234–237. doi:10.1016/j.yexmp.2010.01.004
   PubMed Web of Science ®Google Scholar
• Guo ZY, Jiang LP. Matrix metalloproteinase 12 (MMP12) as an adverse prognostic biomarker of vascular invasion in hepatic cell carcinoma. Eur Rev Med Pharmacol Sci. 2022;26(7):2238–2249. doi:10.26355/eurrev_202204_28454
   PubMed Web of Science ®Google Scholar
• Goffredo V, Gadaleta CD, Laterza A, Vacca A, Ranieri G. Tryptase serum levels in patients suffering from hepatocellular carcinoma undergoing intra-arterial chemoembolization: possible predictive role of response to treatment. Mol Clin Oncol. 2013;1(2):385–389. doi:10.3892/mco.2013.59
   PubMedGoogle Scholar
• Jia ZZ, Jiang GM, Feng YL. Serum HIF-1alpha and VEGF levels pre- and post-TACE in patients with primary liver cancer. Chin Med Sci J. 2011;26(3):158–162. doi:10.1016/s1001-9294(11)60041-2
   PubMedGoogle Scholar
• Yang L, Min X-L, Peng J, Yang K, Yang L, Zhang X-M. The Changes of HIF-1alpha and VEGF Expression After TACE in Patients With Hepatocellular Carcinoma. Int J Med. 2016.
   PubMedGoogle Scholar
• Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008;134(5):703–707. doi:10.1016/j.cell.2008.08.021
   PubMed Web of Science ®Google Scholar
• Xiong XX, Qiu XY, Chen XQ. Advances in Hypoxia-Mediated Mechanisms in Hepatocellular Carcinoma. Mol Pharmacol. 2017;92(3):246–255. doi:10.1124/mol.116.107706
   PubMed Web of Science ®Google Scholar
• Tak E, Lee S, Lee J, et al. Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells. J Hepatol. 2011;54(2):328–339. doi:10.1016/j.jhep.2010.06.045
   PubMed Web of Science ®Google Scholar